Stay current with MiRXES


Media Releases

Keep up to date with our latest news and activities as we continue to innovate and develop our science and technology, bringing novel products to market – from Singapore to the World.

22 September 2022

Singapore-headquartered biotech MiRXES, National University Heart Centre, Singapore (NUHCS) and National Heart Centre Singapore (NHCS) launch SPHERE (Singapore Pulmonary Hypertension Early detection with miRNA biomarkErs) study to identify biomarkers that are relevant to early detection of pulmonary hypertension with the aim to improve Asian patient outcomes and save lives.

18 September 2022

MiRXES announced today the donation of SG$88,902 to the National University Cancer Institute, Singapore (NCIS) Cancer Fund, a sub-fund of NUHS Fund, at the closing ceremony of Let’s Ride! Singapore today, to assist less fortunate cancer patients with critical cancer treatments. This event was graced by Guest-of-Honor, Ms. Low Yen Ling, Minister of State, Ministry of Trade and Industry & Ministry of Culture, Community and Youth, and Mayor of South West District, who witnessed the cheque presentation ceremony.

7 July 2022

MiRXES announced announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd) and also officially opened its R&D and clinical diagnostic labs in Biopolis, Singapore.

7 June 2022

MiRXES has formed a strategic partnership with BGI-Research, an internationally renowned genomics research institution, and MGI, a leading developer and provider of high-throughput sequencing platforms, to accelerate spatio-temporal transcriptomics and multi-omics research in human development and diseases.

27 May 2022

MiRXES announced today the opening of the first industry 4.0 (i4.0) in vitro diagnostic (IVD) manufacturing facility in Southeast Asia. This S$8 million facility at JTC MedTech Hub is the largest i4.0 IVD manufacturing site at in Southeast Asia at 15,000 square feet. Guest-of-Honour, Mr Gan Kim Yong, Minister for Trade and Industry, graced the opening ceremony.

12 April 2022

MiRXES announced today the appointment of Professor Tony Mok, a world-renowned medical oncologist, to its Scientific Advisory Board (SAB). Professor Mok co-founded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group and Asia Thoracic Oncology Research Group and has led multiple multi-national studies that help establish the global standard on personalized medicine for lung cancer.

15 February 2022

MiRXES announced today the set-up of its Hong Kong office and the appointment of Mr. Martin LAW as Managing Director in Hong Kong, who will report to MiRXES’s Co-founder and CEO, Dr. Lihan ZHOU. Mr. Law will lead the establishment and operations of MiRXES Hong Kong Limited, to explore partnerships in providing accurate, affordable and accessible cancer early detection to the Hong Kong and Greater Bay Area communities.

22 November 2021

MiRXES announced today that Dr. Lihan ZHOU, Co-founder and Chief Executive Officer at MiRXES, Dr. Ruiyang ZOU, Co-founder and Chief Technology Officer at MiRXES and Mr. Isaac HO, Chief Investment Officer at MiRXES, have been named EY Entrepreneur Of The Year (EOY) 2021 Singapore by professional services organization, EY.

15 November 2021

MiRXES announced today the appointment of Mr. Dan HEADON as Senior Vice President (SVP), Marketing. Mr. Headon will raise the awareness of MiRXES’s products to patients and customers by partnering closely with the Product, Commercial Operations and Medical Affairs’ teams in launching new products and refining the marketing strategy for MiRXES’s existing products.

23 October 2021

Yayasan MENDAKI and MiRXES , are pleased to announce today the setting up of the “MENDAKI – MIRXES Scholarship” for Malay/Muslim students who are pursuing undergraduate and post-graduate studies in Life and Biomedical Sciences. In addition to the scholarships, the students will also receive internship opportunities and securing employment opportunities with MiRXES upon their graduation.

21 September 2021

MiRXES announced today the appointment of Mr. Da LIU to its Board of Directors. Currently the Managing Director of CR-CP Life Science Fund, Mr. Liu leads investments in life sciences companies globally, especially those in emerging sectors such as RNA therapeutics and cancer screening.

Media Coverage

Stay informed and keep abreast with our media news.

20 Apr 2022

HKET – 疫情加速了科技融入医药学科研范畴,生物科技行业开始获得市场关注。专注于核糖核酸(RNA)科技的新加坡高生物科技企业「觅瑞」(MiRXES),自2014年起致力于研发疾病早诊技术与将其商业化。现时业务遍布香港、中国、日本、美国等45个国家及地区,故吸纳人才成为其首要挑战。 该企藉创造一个较人性化及较灵活的工作环境等3招,以招徕人才。

7 Apr 2022

InvestHK – MiRXES is a biotechnology company founded in 2014. It translates research discoveries to deliver early detection of multiple cancers using proprietary RNA-powered blood tests. In 2021, MiRXES established its Hong Kong office to support its business expansion in the city and in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) to accelerate the global development of a truly preventive healthcare system.


Our partnerships

15 Sep 2021

ヒューマン・メタボローム・テクノロジーズ株式会社 代表取締役社長 橋爪 克仁 、 本社 山形県鶴岡市、以下「 HMT 」 と 、 MiRXES (ミレックサス Chief Executive Officer Zhou Lihan 、本社: シンガポール 、以下「 MiRXES 」 は、 マイクロ RNA 関連製品・サービスを日本において展開することに合意し、販売契約を締結しました 。

31 Aug 2021



Welcome to our knowledge base of insights in the frontiers of the biotech industry.

Congratulations to Associate Professor Too Heng-Phon from the Department of Biochemistry and NUS Centre for Cancer Research at NUS Medicine, who has been conferred the President’s Technology Award 2021.

Across the many functional teams in MiRXES, from R&D to manufacturing and commercial, our women in science wear many different hats — to great success.

Media and Investor Contact

For media enquiries, please email:
For investor enquiries, please email:
Copyright © 2022 MiRXES Pte Ltd. All rights reserved. | Privacy Policy
Scroll to Top